Europium radionuclides in samarium-153-Ethylene Diamine Tetramethylene phosphonic acid (153Sm-EDTMP) radiopharmaceutical waste.

153Sm-EDTMP is widely used as a palliative radiopharmaceutical for treatment of metastatic bone pain. It is produced by neutron activation of enriched 152Sm targets in a nuclear reactor. The long-lived europium radionuclides are co-produced along with production of 153Sm and it give rise to radioactive waste in 153Sm-EDTMP production. The gamma radiation dose rate was found significant on the radioactive waste generated during the production of 153Sm-EDTMP. Residual activity in six waste samples generated in different batches of 153Sm-EDTMP production were analysed for percentage contributions of 152,154,155Eu using gamma-ray spectrometry. 154Eu was a major contributor with around 62%, and the other radioisotopes, viz. 152Eu &155Eu contribution were ∼29% & ∼9% respectively. The activity concentration of these long-lived europium radionuclides in samarium radiopharmaceutical production waste may be utilised for the dose rate estimation, and vice versa.

Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model.

Respiratory syncytial virus (RSV) causes bronchiolitis in young children and common colds in adults. There is no licensed vaccine, and prophylactic treatment with palivizumab is very expensive and limited to high-risk infants. Ribavirin is used as an antiviral treatment in infants and immunosuppressed patients, and its use is limited due to side-effects, toxicity to the recipient and staff, and evidence of marginal clinical efficacy. Therefore, we studied the in vivo kinetics, and the antiviral and protective properties of a novel candidate for RSV disease treatment. The drug is a small molecule (TMC353121) discovered by screening for fusion inhibitory properties against RSV in a cellular infection model. The pharmacokinetics of TMC353121 was studied in BALB/c mice and antiviral effects determined by testing viral loads in lung tissue by quantitative RT-PCR and plaque assay after intranasal RSV infection. At doses of 0.25-10 mg · kg(-1), TMC353121 significantly reduced viral load, bronchoalveolar lavage cell accumulation and the severity of lung histopathological change after infection. Treatment remained effective if started within 48 h of infection, but was ineffective thereafter. Therefore, TMC353121 is a novel potent antiviral drug, in vivo reducing RSV replication and inhibiting consequential lung inflammation, with a great potential for further clinical development.

Leptospirosis in children.

Leptospirosis has a broad spectrum of clinical manifestations varying, from inapparent influenza like illness to fulminant fatal disease with hepato-renal dysfunction and hemorrhagic phenomena. Our cases had fever, puffiness, respiratory distress and bleeding diathesis as leading manifestations. Leptospirosis was suspected in view of epidemic situation prevailing in the city. We report four cases here, three of which survived and one died.

Nineteen-millimeter aortic St. Jude Medical heart valve prosthesis: up to sixteen years' follow-up.

UNLABELLED: BACKGROUND; Prosthetic valve replacement in a small aortic root without annulus enlargement raises concern about its long-term benefits. METHODS: Between July 1979 and June 1994, 104 (18%) of 593 patients underwent aortic valve replacement using the 19-mm St. Jude Medical heart valve prosthesis. There were 93 women and 11 men, with a mean age of 66.2 +/- 10.6 years. Forty-four patients (42%) were 70 or more years old. The mean body surface area was 1.61 +/- 0.16 m2 (range, 1.2 to 2.1 m2). Forty-nine patients (47%) underwent concomitant procedures; 23 patients (22%) required coronary artery bypass grafts and 25 patients (24%), mitral valve replacement. Ninety-eight patients (94%) presented in New York Heart Association class III and IV. RESULTS: The operative mortality was 7.6% (8 patients). Follow-up was 100% with a mean of 5.48 +/- 3.73 years (range, 1 to 16 years) and a total of 708 patient-years. There were 18 late deaths, with a mortality of 2.5% patient-years. The incidence of thromboembolism was 0.4% patient-years (3 patients) and anticoagulant-related morbidity was 0.85% patient-years (6 patients). Long-term survival in the two groups with a body surface area of less than 1.7 m2 and 1.7 m2 or more was not statistically different (p = 0.30). The univariate analysis with body surface area as a predictor of mortality showed that a larger body surface area had no effect on the long-term mortality (chi2 p value = 0.36). Survival for 5 and 10 years with the 95% confidence interval was 80.6% +/- 8.3% and 61.6% +/- 15%. Freedom from thromboembolism was 96.3% +/- 4.2% and anticoagulant-related hemorrhage was 91.8% +/- 6.8% at the end of 16 years. Cox proportional hazards model, with time-dependent covariates, showed that events of thromboembolism, anticoagulant-related hemorrhage, and myocardial infarction during follow-up increased the risk of late death (risk ratio, 9.5, 10.3, and 32.8, respectively). The age at operation was an independent risk factor, with decreased survival with age 70 or more years (p = 0.0002). However, body surface area (p = 0.97) and concomitant cardiac procedures (p = 0.86) were not statistically significant predictors of death. CONCLUSIONS: The long-term performance of the 19-mm St. Jude Medical heart valve prosthesis in the small aortic root is satisfactory irrespective of the body surface area, and it is a viable alternative for such patients.

St. Jude Medical cardiac valves in small aortic roots: follow-up to sixteen years.

Prosthetic aortic valve replacement in the small aortic root raises concerns of its long-term effects. Between 1978 and 1994, 270 patients received only small aortic prostheses (< or = 21 mm). There were 117 men (43.3%) and 153 women (56.7%) with a mean age of 64.3 +/- 11.6 years (range 19 to 87 years). The body surface areas ranged from 1.2 to 2.26 m2 (mean 1.71 +/- 0.27 m2). Ninety-one percent of patients had New York Heart Association class III or IV symptoms and 33% underwent concomitant coronary artery bypass grafting. The operative mortality rate was 3.3% (9 deaths) and follow-up (100%) extended from 1 to 16 years (mean 6.2 +/- 3.9 years) with cumulative survival of 1676 patient-years. There were 55 late deaths (3.28% per patient-year). The linearized rates of morbidity reported as percent per patient-year were as follows: structural failure, 0%; paravalvular leak, 0.12%; prosthetic endocarditis, 0.24%; anticoagulant-related morbidity, 1.24%; and thromboembolism, 1.10%. In 89% of the survivors New York Heart Association functional performance had improved to class II or I. The actuarial survival with 95% confidence intervals at 5, 10, and 16 years was 86.9% (82.5%, 91.3%), 68.6% (60.6%, 76.6%), and 53.6% (36.6%, 70.6%), respectively. Freedom from late valve-related events (95% confidence intervals) at 10 and 16 years was as follows: thromboembolism, 91.2% (86.6%, 95.8%) and 78.3% (62.6%, 94%); anticoagulant-related morbidity, 89.1% (83.8%, 94.4%) and 81.0% (65.1%, 96.9%); and prosthetic endocarditis, 98.8% (97.5%, 100%) and 98.8% (97.5%, 100%), respectively. Multivariate analysis revealed age at operation, myocardial infarction, and endocarditis affected the long-term survival. The risk of sudden death irrespective of body surface area and valve size was not statistically different. Thus the long-term performance of the St. Jude Medical valve in small aortic roots is satisfactory.

Management of unresectable oesophageal cancer: a review of 537 patients.

We compared and contrasted the potentials of palliation afforded by various management methods in a retrospective study of all patients referred to one surgical team in a 20-year period. Five hundred thirty-seven patients had unresectable oesophageal cancer. There were five treatment groups: group 1-dilatation plus external radiotherapy (DXR, n = 95), group 2-gastrostomy plus DXR (n = 18), group 3-permanent intubation (n = 329), group 4-oesophageal bypass (BP, n = 70), and group 5-YAG laser plus brachytherapy (n = 25). Groups 1 and 2 had high mortality (4% and 25%) and poor symptom relief, with an average survival of 2.5 and 3.5 months, respectively. Group 3 had a 20% mortality rate, moderate-to-good symptom relief and an average survival of 4.2 months. This method was best for lower oesophageal cancer. Group 4 had a 22% mortality rate, good symptom relief and an average survival of 10.5 months. The BP method was suitable for patients with oesophago-airway fistula (OAF) and those with lower oesophageal cancer found unresectable at operation. Group 5 had a hospital mortality rate of 8%, good symptom control and an average survival of 6.2 months. This was suitable for all patients (except those with OAF). In palliation of carcinoma of the oesophagus the selection of method should be made to suit the characteristic and location of the tumour.

Unusual variant of pulmonary arteriovenous communication.

We report a case of direct communication of right pulmonary artery to left atrium , a very rare congenital anomaly treated surgically with complete success at our centre.